J&J Declares ‘Sustained Disease Control’ With Bladder Cancer Drug-Device Combo

The targeted drug release device TAR-200 shows promising response and disease-free survival rates in specific populations of patients with non-muscle-invasive bladder cancer.

Scroll to Top